
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Aging (Albany NY)</journal-id><journal-id journal-id-type="publisher-id">ImpactJ</journal-id><journal-title-group><journal-title>Aging</journal-title></journal-title-group><issn pub-type="epub">1945-4589</issn><publisher><publisher-name>Impact Journals LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">20157552</article-id><article-id pub-id-type="pmc">2806046</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Human insulin/IGF-1 and familial longevity at middle age</article-title><alt-title alt-title-type="running-head">Insulin/IGF-1 and familial longevity</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rozing</surname><given-names>Maarten P.</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Westendorp</surname><given-names>Rudi G.J.</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Fr&#x000f6;lich</surname><given-names>Marijke</given-names></name><xref ref-type="aff" rid="A3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>de Craen</surname><given-names>Anton J.M.</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Beekman</surname><given-names>Marian</given-names></name><xref ref-type="aff" rid="A4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Heijmans</surname><given-names>Bastiaan T.</given-names></name><xref ref-type="aff" rid="A4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mooijaart</surname><given-names>Simon P.</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Blauw</surname><given-names>Gerard-Jan</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Slagboom</surname><given-names>P. Eline</given-names></name><xref ref-type="aff" rid="A4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>van Heemst</surname><given-names>Diana</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Group</surname><given-names>on behalf of the Leiden Longevity Study (LLS)</given-names></name></contrib></contrib-group><aff id="A1"><sup>1</sup> Department of Gerontology and Geriatrics, Leiden University Medical Center, 2300 RC, Leiden, the Netherlands
            </aff><aff id="A2"><sup>2</sup> Netherlands Consortium for Healthy Ageing (NCHA) 
            </aff><aff id="A3"><sup>3</sup> Department of Clinical Chemistry, Leiden University Medical Center, 2300 RC, Leiden, the Netherlands
            </aff><aff id="A4"><sup>4</sup> Department of Molecular Epidemiology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands
            </aff><author-notes><corresp id="cor1"><bold>Correspondence: </bold>Diana van
                        Heemst, PhD, Department of Gerontology and Geriatrics, Leiden University
                        Medical Center, PO Box 9600, 2300 RC, Leiden, the Netherlands  <email>D.van_Heemst@lumc.nl</email></corresp></author-notes><pub-date pub-type="collection"><month>8</month><year>2009</year></pub-date><pub-date pub-type="epub"><day>24</day><month>7</month><year>2009</year></pub-date><volume>1</volume><issue>8</issue><fpage>714</fpage><lpage>722</lpage><history><date date-type="received"><day>20</day><month>5</month><year>2009</year></date><date date-type="accepted"><day>22</day><month>7</month><year>2009</year></date></history><permissions><copyright-statement>Copyright: &#x000a9;2009 Rozing et al.</copyright-statement><copyright-year>2009</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>
                        Recently,
                        we have shown that compared to controls, long-lived familial nonagenarians
                        (mean age: 93.4 years) from the Leiden Longevity Study displayed a lower
                        mortality rate, and their middle-aged offspring displayed a lower
                        prevalence of cardio-metabolic diseases, including diabetes mellitus. The
                        evolutionarily conserved insulin/IGF-1 signaling (IIS) pathway has been
                        implicated in longevity in model organisms, but its relevance for human
                        longevity has generated much controversy. Here, we show that compared to
                        their partners, the offspring of familial nonagenarians displayed similar
                        non-fasted serum levels of IGF-1, IGFBP3 and insulin but lower non-fasted
                        serum levels of glucose, indicating that familial longevity is associated
                        with differences in insulin sensitivity.
                </p></abstract><kwd-group><kwd>familial longevity</kwd><kwd>height</kwd><kwd>glucose handling</kwd><kwd>IGF-1</kwd><kwd>IGFBP3</kwd></kwd-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>In Western societies, life expectancy has
                        increased dramatically over the last century, but striking inter-individual
                        differences in life expectancy remain [<xref ref-type="bibr" rid="R1">1</xref>]. Ample
                        evidence has shown that healthy longevity is determined by a mix of genetic,
                        environmental and chance elements. Because the odds of exceptional longevity
                        runs in families, we designed the Leiden Longevity Study [<xref ref-type="bibr" rid="R2">2</xref>]. Recently,
                        we have shown that the nonagenarian siblings included in the Leiden Longevity
                        Study displayed a 41% lower risk of mortality compared to sporadic nonagenarians
                        [<xref ref-type="bibr" rid="R3">3</xref>]. Moreover, compared
                        to their partners, the offspring of nonagenarian
                        siblings displayed a significantly lower prevalence of myocardial infarction,  hypertension and diabetes mellitus [<xref ref-type="bibr" rid="R3">3</xref>]. The
                        differences in clinical phenotype observed after selection for familial
                        longevity are in line with the lower prevalence of cardio-metabolic disease
                        previously detected when offspring from sporadic centenarians were compared to
                        offspring of parents who had died at average age [<xref ref-type="bibr" rid="R4">4</xref>] and when
                        offspring from sporadic centenarians were compared to their partners [<xref ref-type="bibr" rid="R5">5</xref>]. Moreover,
                        the observed lower mortality rate at high ages and better preservation of health
                        at middle age indicates that resilience against disease and death may have
                        similar underlying biological mechanisms that are influenced by genetic or
                        familial factors.
                    
            </p><p>Of the genetically determined pathways that have been
                        implicated in longevity in a variety of different model organisms,  the evolutionarily conserved insulin/IGF-1 signaling (IIS) pathway clearly stands out in current
                        literature (reviewed in [<xref ref-type="bibr" rid="R6">6</xref>]). Mutations
                        in IIS components were first found to affect reproduction, metabolism, stress
                        response and life span in <italic>C. elegans</italic> (reviewed in [<xref ref-type="bibr" rid="R7">7</xref>]). The link
                        between reduced IIS signaling and longevity was subsequently also observed in <italic>D.
                                melanogaster</italic>. Mutants in the <italic>D</italic>. <italic>melanogaster</italic> insulin receptor<italic>InR </italic>[<xref ref-type="bibr" rid="R8">8</xref>] and
                        in the insulin receptor substrate <italic>CHICO </italic>[<xref ref-type="bibr" rid="R9">9</xref>] are both
                        long-lived. Strikingly however, in both cases the long-lived phenotype was only
                        observed for females. In addition to being long-lived, these <italic>D. melanogaster</italic>
                        females are small, obese and infertile. In mice, selective disruption of the
                        insulin receptor in the adipose tissue leads to a reduction in fat mass and
                        extended longevity [<xref ref-type="bibr" rid="R10">10</xref>]. Increases
                        in lifespan were also reported in mice with deletion of insulin receptor
                        substrate 1 (IRS1) in whole body [<xref ref-type="bibr" rid="R11">11</xref>] or IRS2
                        only in the brain [<xref ref-type="bibr" rid="R12">12</xref>]. Moreover,
                        dwarf mice exhibiting GH deficiency
                            or resistance, including <italic>Prop1<sup>df/d</sup></italic>[<xref ref-type="bibr" rid="R13">13</xref>], <italic>Pit1<sup>dw/dw</sup></italic>[<xref ref-type="bibr" rid="R14">14</xref>], <italic>GHRHR<sup>lit/lit</sup></italic>[<xref ref-type="bibr" rid="R14">14</xref>] and <italic>GHR<sup>-/-</sup></italic>[<xref ref-type="bibr" rid="R15">15</xref>] all display
                        hypoinsulinemia and enhanced insulin sensitivity along with extended longevity.
                        In mice heterozygous for <italic>igf1r </italic>deletion (<italic>Igf1r<sup>+/-</sup></italic>[<xref ref-type="bibr" rid="R16">16</xref>]) or
                        containing a hypomorphic <italic>igf1r</italic> mutation (Midi mice [<xref ref-type="bibr" rid="R11">11</xref>]), only
                        females, but not males, exhibited the long-lived phenotype.
                    
            </p><p>Based on the similarities among the
                        insulin/IGF-1 pathways in animals and humans, the possibility that
                        modifications in the insulin/IGF-I signaling system could also extend lifespan
                        in humans has been suggested. However, separating the roles of insulin and
                        IGF-1 in mammals and their relevance for human healthy longevity has been
                        difficult and generated much controversy. In humans, relatively low IGF-I
                        levels have been associated with an increased risk of developing cardiovascular
                        disease and diabetes, while relatively high IGF-I levels have been associated
                        with an increased risk of developing cancer [<xref ref-type="bibr" rid="R17">17</xref>]. Moreover,
                        in humans, an age-related decline in IGF-1 levels occurs [<xref ref-type="bibr" rid="R18">18</xref>], and at old
                        age, low IGF-1 levels are associated with frailty [<xref ref-type="bibr" rid="R19">19</xref>], poor
                        nutrition and cognitive decline [<xref ref-type="bibr" rid="R20">20</xref>] and an
                        increased risk of death [<xref ref-type="bibr" rid="R21">21</xref>]. On the
                        other hand, genetic variation in genes associated with down-regulation of the IIS
                        pathway has been associated with human longevity in several instances,
                        although, when moving up the evolutionary ladder, together with an increase in
                        genome complexity, effect sizes became smaller [<xref ref-type="bibr" rid="R22">22</xref>]. Two
                        studies have shown evidence for a role for genetic variation in the IIS pathway
                        in body height as well as human longevity. First, earlier we found an association
                        between genetic variation associated with
                        reduced IIS pathway activity and shorter stature as well as improved old age
                        survival in sporadic female octogenarians [<xref ref-type="bibr" rid="R23">23</xref>]. Second,
                        offspring of sporadic female centenarians were shown to be smaller and display
                        higher IGF-1 levels, indicative of IGF-1 insensitivity, while rare IGF-1R
                        mutations associated with IGF-1 insensitivity were found enriched in
                        centenarians [<xref ref-type="bibr" rid="R24">24</xref>]. Here, to
                        investigate whether these results could be generalized to familial longevity,
                        we have compared key anthropometric
                        measures as well as serum parameters related to insulin/IGF-1 signaling in a
                        group of middle-aged offspring of nonagenarian siblings and a control group of
                        their partners of the Leiden Longevity Study.
                    
            </p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2_1"><title>Metabolic characteristics of offspring compared to
                            partners
                        </title><p>Table <xref ref-type="table" rid="T1">1</xref> depicts the demographic and metabolic
                                characteristics of the groups from the Leiden Longevity Study that were used
                                for the present study. The group of offspring proportionately contained less
                                diabetics than the group of partners (p = 0.001). After exclusion of diabetics,
                                the group of offspring had lower non-fasted serum levels of glucose (p = 0.002)
                                than the group of partners.  In addition, the group of offspring had a slightly
                                more favorable lipid profile as compared to the group of partners.
                            
                </p></sec><sec id="s2_2"><title>IGF-1/IGFBP3 and non-fasted glucose
                        </title><p>Next we assessed whether the lower glucose levels
                            observed among the group of offspring relative to thegroup of partners could be driven by
                            differences in IGF-1 axis parameters.  Therefore we determined the association
                            between serum IGF-1 / IGFBP3 molar ratios and non-fasted serum glucose levels.
                            Higher ratios of IGF-1/ IGFBP3 were associated with lower serum glucose levels.
                            One standard deviation increase in IGF-1/IGFBP3 ratio was associated with a
                            decrease of 0.10 mmol/L serum glucose (SE: 0.05) among the group of partners (p
                            = 0.05). The difference between partners and offspring in the change of glucose
                            levels per standard deviation IGF-1/IGFBP3 ratio was not significant: 0.02 (SE:
                            0.06) nmol/L per year (p for interaction&#x000a0;=&#x000a0;0.70).
                        
                </p></sec><sec id="s2_3"><title>Measures of the IGF-1 axis in offspring compared to
                            partners
                        </title><p>Table <xref ref-type="table" rid="T2">2</xref> shows the comparison between the groups of offspring
                                and partners for various IGF-1 axis parameters for males and females
                                separately. In order to detect the effect of possible genetic differences in
                                IGF-1 signaling between offspring and partners, we also determined
                                anthropometrical characteristics in subjects of both study groups
                                (Table&#x000a0;2). With regard to serum IGF-1 axis parameters, no differences were
                                observed between the group of offspring and the group of partners in both
                                sexes. Likewise, the study groups showed no differences in terms of
                                sex-specific body stature, i.e. height, weight and body mass index.
                            
                </p><p>Next, we determined whether the
                            distribution of serum IGF-1 axis parameters and anthropometrical parameters were different between offspring and partners.  Figure <xref ref-type="fig" rid="F1">1</xref> displays the cumulative distributions of IGF-1, IGFBP3
                            and height among partners and offspring for both sexes separately. No
                            differences in height were observed between offspring and partners in the tails
                            of the IGF-1 and IGFBP3 distribution curves. Taken together, the cumulative
                            distribution curves do not suggest enrichment of high or low IGF-1 axis
                            parameters nor large or short statures among the groups of offspring versus
                            partners.
                        
                </p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1.</label><caption><title>Comparison of demographics and serum parameters between offspring and partners for males and females combined.</title><p>
                                    *Age is presented as median with interquartile range. Serum parameters are presented as mean values with 95% confidence intervals.  Mean values, 95% confidence intervals and p-values were calculated using a linear regression model, adjusted for age and sex. LDL denotes low-density lipoprotein and HDL high-density lipoprotein.
                                    **Data are presented as geometric means with 95% confidence intervals.
                                    &#x02020; Mean values, standard error of the mean and p-value for Total cholesterol, LDL cholesterol, HDL cholesterol, , Triglycerides and Free Fatty Acids were adjusted for lipid lowering agents (fibrates, niacin, bile acid sequestrants, 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors).
                                
                        </p></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
                                                      Offspring
                                                
                                </td><td rowspan="1" colspan="1">
                                                      Partners
                                                
                                </td><td colspan="2" rowspan="1">
                                                      p-value
                                                
                                </td></tr></thead><tbody><tr><td rowspan="1" colspan="1"><bold>Demographics</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td colspan="2" rowspan="1"/></tr><tr><td rowspan="1" colspan="1">
                                                         Participants - n
                                                
                                </td><td rowspan="1" colspan="1">
                                                      1171
                                                
                                </td><td rowspan="1" colspan="1">
                                                      542
                                                
                                </td><td colspan="2" rowspan="1"/></tr><tr><td rowspan="1" colspan="1">
                                                         Diabetics - n (%)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      46 (3.9)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      42 (7.7)
                                                
                                </td><td colspan="2" rowspan="1"><bold>0.001</bold></td></tr><tr><td rowspan="1" colspan="1">
                                                         Females - n (%)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      633 (54.1)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      302 (55.7)
                                                
                                </td><td colspan="2" rowspan="1">
                                                      0.57
                                                
                                </td></tr><tr><td rowspan="1" colspan="1">
                                                         Age  (year)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      59.2 (55.0 - 64.1)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      58.8 (54.3 - 63.7)
                                                
                                </td><td colspan="2" rowspan="1">
                                                      0.15
                                                
                                </td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td colspan="2" rowspan="1"/></tr><tr><td rowspan="1" colspan="1"><bold>Serum
                                                              parameters (non-diabetics)
                                                        </bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td colspan="2" rowspan="1"/></tr><tr><td rowspan="1" colspan="1">
                                                         Participants - n
                                                
                                </td><td rowspan="1" colspan="1">
                                                      1125
                                                
                                </td><td rowspan="1" colspan="1">
                                                      500
                                                
                                </td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
                                                         Glucose  (mmol/L)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      5.69 (5.62 - 5.76)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      5.87 (5.76 - 5.97)
                                                
                                </td><td rowspan="1" colspan="1"><bold>0.002</bold></td></tr><tr><td rowspan="1" colspan="1">
                                                         Insulin  (mU/L )**
                                                
                                </td><td rowspan="1" colspan="1">
                                                      14.4 (13.6 - 15.4)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      15.4 (14.0 -16.8)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      0.21
                                                
                                </td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
                                                         Total cholesterol  (mmol/L)&#x02020;
                                                
                                </td><td rowspan="1" colspan="1">
                                                      5.56 (5.47 - 5.65)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      5.62 (5.52 - 5.72)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      0.40
                                                
                                </td></tr><tr><td rowspan="1" colspan="1">
                                                         LDL cholesterol (mmol/L)&#x02020;
                                                
                                </td><td rowspan="1" colspan="1">
                                                      3.32 (3.24 - 3.39)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      3.37 (3.29 - 3.45)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      0.33
                                                
                                </td></tr><tr><td rowspan="1" colspan="1">
                                                         HDL cholesterol  (mmol/L)&#x02020;
                                                
                                </td><td rowspan="1" colspan="1">
                                                      1.46 (1.42 - 1.49)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      1.43 (1.39 - 1.47)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      0.24
                                                
                                </td></tr><tr><td rowspan="1" colspan="1">
                                                         Triglycerides (mmol/L) **,&#x02020;
                                                
                                </td><td rowspan="1" colspan="1">
                                                      1.50 (1.44 - 1.55)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      1.57 (1.50 - 1.65)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      0.09
                                                
                                </td></tr><tr><td rowspan="1" colspan="1">
                                                         Free fatty acids (mmol/L) **,&#x02020;
                                                
                                </td><td rowspan="1" colspan="1">
                                                      0.27 (0.26 - 0.28)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      0.27 (0.26 - 0.29)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      0.38
                                                
                                </td></tr><tr><td colspan="5" rowspan="1"/></tr></tbody></table></table-wrap><fig id="F1" orientation="portrait" position="float"><label>Figure 1.</label><caption><title>Cumulative distribution curves of serum IGF-1 levels, serum IGFBP3 levels and height.</title><p>
                                            Cumulative distribution curves of IGF-1 levels for offspring and partners
                                            among females (<bold>A</bold>) and males (<bold>B</bold>); Cumulative distribution
                                            curves of IGFBP3 levels for offspring and partners among females (<bold>C</bold>)
                                            and males (<bold>D</bold>); Cumulative distribution curves of height for
                                            offspring and partners among females (<bold>E</bold>) and males (<bold>F</bold>). Black
                                            lines represent offspring, gray lines represent partners.
                                    
                        </p></caption><graphic xlink:href="aging-01-714-g001"/></fig><p>IGF-1 levels have been
                            consistently reported to progressively decline with age. To determine whether
                            this observation applied to the groups that were used in the present study, we
                            assessed the association between serum IGF-1 levels and serum IGFBP3 levels
                            with age. Figure <xref ref-type="fig" rid="F2">2</xref> displays the sex-specific serum IGF-1 and IGFBP3 levels for
                            different age categories among offspring and partners.  Serum IGF-1 levels
                            declined with age in both female partners
                            (-0.14 (SE: 0.04) nmol peryear increase; p&#x0003c;0.001) and male partners (-0.16
                            (SE: 0.05) nmol/L per year increase; p
                            =0.001). The difference in annual change in serum IGF-1 levels between partners
                            and offspring was not significant: 0.01 (SE: 0.05) nmol/L per year (p for
                            interaction= 0.79) for females and 0.01 nmol/L (SE: 0.06) per year (p for
                            interaction=0.83) for males. Similarly, no differences between partners and
                            offspring were observed in terms of annual change in serum IGFBP3 levels: 0.01
                            mg/L (SE: 0.01) (p for interaction = 0.47) for females and 0.02 mg/L (SE: 0.01)
                            (p for interaction =0.10) for males.
                        
                </p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2.</label><caption><title>Comparison of anthropometrics and IGF-1 axis parameters between offspring and partners for females and males separately.</title><p>
                                   Data are presented as means with 95% confidence intervals. All analyses were adjusted for age.
                                   *Diabetic subjects were excluded from analyses.
                               
                        </p></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
                                                      Offspring*
                                                
                                </td><td rowspan="1" colspan="1">
                                                      Partners*
                                                
                                </td><td rowspan="1" colspan="1">
                                                      p-value
                                                
                                </td></tr></thead><tbody><tr><td rowspan="1" colspan="1"><bold>Females (n)</bold></td><td rowspan="1" colspan="1">
                                                      610
                                                
                                </td><td rowspan="1" colspan="1">
                                                      286
                                                
                                </td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
                                                         IGF-1 axis serum parameters
                                                
                                </td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
                                                           IGF-1  (nmol/L)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      17.1 (16.7 - 17.5)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      17.1 (16.5 - 17.7)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      0.99
                                                
                                </td></tr><tr><td rowspan="1" colspan="1">
                                                           IFGBP3 (mg/L)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      4.44 (4.36 - 4.53)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      4.47 (4.36 - 4.57)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      0.72
                                                
                                </td></tr><tr><td rowspan="1" colspan="1">
                                                           IGF-1/ IGFBP3 (molar ratio)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      0.11 (0.11 - 0.11))
                                                
                                </td><td rowspan="1" colspan="1">
                                                      0.11 (0.11 - 0.11)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      0.60
                                                
                                </td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
                                                         Anthropometrics
                                                
                                </td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
                                                           Height (m)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      166.8 (166.2 - 167.3)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      166.9 (166.1 - 167.7)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      0.79
                                                
                                </td></tr><tr><td rowspan="1" colspan="1">
                                                           Weight (kg)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      69.2 (68.2 - 70.3)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      70.2 (68.9 - 71.6)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      0.25
                                                
                                </td></tr><tr><td rowspan="1" colspan="1">
                                                           Body Mass Index (kg/m<sup>2</sup>)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      24.9 (24.5 - 25.3)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      25.2 (24.8 - 25.7)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      0.25
                                                
                                </td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><bold>Males (n)</bold></td><td rowspan="1" colspan="1">
                                                      515
                                                
                                </td><td rowspan="1" colspan="1">
                                                      214
                                                
                                </td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
                                                         IGF-1 axis serum parameters
                                                
                                </td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
                                                           IGF-1  (nmol/L)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      17.5 (17.0 - 17.9)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      17.3 (16.6 - 18.0)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      0.75
                                                
                                </td></tr><tr><td rowspan="1" colspan="1">
                                                           IGFBP3 (mg/L)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      4.22 (4.13 - 4.30)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      4.20    (4.08 - 4.32)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      0.85
                                                
                                </td></tr><tr><td rowspan="1" colspan="1">
                                                           IGF-1/ IGFBP3 (molar ratio)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      0.12 (0.12 - 0.12)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      0.12 (0.12 - 0.12)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      0.82
                                                
                                </td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
                                                         Anthropometrics
                                                
                                </td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
                                                           Height (m)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      178.7 (178.1 - 179. 4)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      179.1 (178.2 - 180.0)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      0.44
                                                
                                </td></tr><tr><td rowspan="1" colspan="1">
                                                           Weight (kg)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      82.0 (80.9 - 83.0)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      82.4 (80.8 - 84.1)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      0.61
                                                
                                </td></tr><tr><td rowspan="1" colspan="1">
                                                           Body Mass Index (kg/m<sup>2</sup>)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      25.6 (25.4 - 25.9)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      25.7 (25.2 - 26.1)
                                                
                                </td><td rowspan="1" colspan="1">
                                                      0.96
                                                
                                </td></tr></tbody></table></table-wrap></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>The main findings of this study are
                        twofold. First, consistent with the lower prevalence of diabetes observed
                        earlier, non-fasted serum glucose levels were lower in the offspring of
                        familial nonagenarians when compared to their partners. Second, we did not
                        observe differences in non-fasted serum levels of IGF-1, IGFBP3 or in height
                        between the groups of offspring and partners, nor in the rate of the decline of
                        levels of IGF-1 or IGFBP3 over chronological age. Taken together,  these data indicate that familial longevity is associated with differences in glucose handling, which
                        are not explained by major differences in IGF-1 and/or IGFBP3 levels.
                    
            </p><p>The link between reduced IIS activity and longevity is
                        evolutionarily conserved from worms to rodents, with effects on longevity often
                        being stronger in the female sex. However, separating the roles of insulin and
                        IGF-1 in mammals has been very difficult and generated much controversy.
                        Because the actions of GH, insulin and IGF-1 are largely interwoven, genetic
                        modification of the GH/IGF-1 axis in mammals also entails differences in the
                        regulation of glucose metabolism. Interestingly, the hallmark phenotype of all
                        long-lived mouse models containing mutations that induce GH/IGF-1 deficiency or
                        resistance, is their enhanced insulin sensitivity [<xref ref-type="bibr" rid="R6">6</xref>]. Previously,
                        we observed a lower prevalence of diabetes in the offspring group [<xref ref-type="bibr" rid="R3">3</xref>]. Here, we
                        show that after exclusion of all diabetics, lower non-fasted glucose levels
                        were observed in the group of offspring of familial nonagenarians as compared
                        to the partners. The lower non-fasted glucose levels in offspring compared to
                        partners are suggestive of a better glucose handling and/or higher insulin
                        sensitivity in familial longevity, which is in line with the hallmark phenotype
                        observed in the many long-lived mammalian IIS mutants. Other data also support
                        a link between preserved insulin sensitivity and human longevity. While insulin
                        sensitivity generally declines with age in humans [<xref ref-type="bibr" rid="R25">25</xref>], sporadic
                        long-lived centenarians have been shown to exhibit an exquisite insulin
                        sensitivity, comparable to that of young adults [<xref ref-type="bibr" rid="R26">26</xref>].
                    
            </p><fig id="F2" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Association
                                        between age categories and serum IGF-1 levels for offspring and partners
                                        among females (<bold>A</bold>) and males (<bold>B</bold>) and association between age
                                        categories and serum IGFBP3 levels for offspring and partners among females
                                        (<bold>C</bold>) and males (<bold>D</bold>). Dark bars represent offspring, light bars
                                        represent partners. Number of participants per age category for females
                                        (offspring/ partners): category &#x0003c;55: 156/110; category 55-60: 194/83; category
                                        60-65: 146/66; category &#x0003e;65: 114/27.  Number of participants per age
                                        category for males (offspring/ partners): category &#x0003c;55: 133/42; category
                                        55-60: 140/49; category 60-65: 140/57; category &#x0003e;65: 102/66.
                                
                    </p></caption><graphic xlink:href="aging-01-714-g002"/></fig><p>The preserved insulin sensitivity observed in
                        centenarians, co-occurred with relatively high levels of IGF-1/IGFBP3, which
                        has lead to the suggestion of causal link between the preserved insulin
                        sensitivity and levels of IGF-I/IGFBP3 [<xref ref-type="bibr" rid="R27">27</xref>]. In rats,
                        IGF-1 and IGFBP3 were shown to have opposing (centrally mediated) effects on glucose metabolism, with IGF-1 acting as an insulin
                        sensitizer, and IGFBP3 as an insulin inhibitor [<xref ref-type="bibr" rid="R28">28</xref>]. Similarly, in humans, IGF-1
                        administration was found to increase glucose uptake and inhibit hepatic glucose
                        production in healthy subjects [<xref ref-type="bibr" rid="R29">29</xref>], and low serum IGF-1 levels were
                        found associated with glucose intolerance [<xref ref-type="bibr" rid="R30">30</xref>]. In line with these findings, we
                        also observed a negative association between IGF-1/IGFBP3 levels and non-fasted
                        glucose levels in both our study groups, but neither this association nor the
                        mean levels of IGF-1 and IGFBP3 were different between the offspring and
                        partner groups. Our observation of improved glucose handling in the absence of
                        major differences in IGF-1/IGFBP3 levels resembles  the Effects observed upon caloric restriction in humans.
                        In contrast to model organisms, in humans, IGF-1 levels were not found to be
                        decreased upon caloric restriction, while insulin sensitivity was increased
                        upon caloric restriction in humans as in model organisms [<xref ref-type="bibr" rid="R31">31</xref>]. The lack
                        of differences in BMI, as well as preliminary data on food intake, indicate
                        however that the observed difference in glucose handling between the groups of offspring
                        and partners can not be explained by a lower caloric intake in the offspring
                        group.
                    
            </p><p>The observation of improved
                        glucose handling in the absence of major differences in IGF-1/IGFBP3 in
                        familial longevity does not rule out the possibility that genetic variations
                        affecting IGF-1/IGFBP3 levels do contribute to human longevity. Recently, it
                        was shown that centenarians exhibited a relative enrichment for rare genetic
                        variants in the IGF-1 receptor which resulted in high levels of IGF-1/IGFBP3
                        coexisting with low levels of IGF-1 signaling [<xref ref-type="bibr" rid="R24">24</xref>]. Also,
                        earlier we and others showed that common genetic variations affecting IGF-1
                        signaling might contribute to differences in mortality in the population at
                        large [<xref ref-type="bibr" rid="R23">23</xref>,<xref ref-type="bibr" rid="R32">32</xref>], but
                        the phenotypic effects associated with such variants (smaller stature,
                        differences in serum levels of IGF-1 and/or IGFBP3) do not form a distinctive
                        part of the hallmark phenotype of preserved glucose handling which we found
                        associated with familial longevity.
                    
            </p></sec><sec id="s4" sec-type="methods"><title>Methods</title><p>
                <underline>Leiden
                </underline>
                <underline> Longevity Study.
                </underline> In the Leiden Longevity Study, 420 families were recruited consisting
                        of long-lived Caucasian siblings together with their offspring and the partners
                        thereof [<xref ref-type="bibr" rid="R2">2</xref>,<xref ref-type="bibr" rid="R23">23</xref>].
                        Families were recruited if at least two long-lived siblings were alive and
                        fulfilled the age-criterion of 89 years or older for males and 91 year or older
                        for females. There were no selection criteria
                        on health or demographic characteristics. For 2465 of the offspring and their
                        partners, non-fasted serum samples taken at baseline were available for the
                        determination of endocrine and metabolic parameters. Between November 2006 and
                        May 2008, for 2235 of the offspring and their partners, information on medical
                        history was obtained from the participants' general practitioner (response:
                        91%). For 2255 of the offspring and their partners, information on the use of
                        medication was obtained from the participants' pharmacy (response: 92%). For
                        2184 of the offspring and partners a general questionnaire containing information
                        on lifestyle and self-reported height and weight was obtained (response: 89%).
                        For the present study, for a total of 1713 of the offspring and their partners,
                        serum as well as information on medical history on diabetes and information on
                        medication use and the general questionnaire were available (inclusion: 70%).
                        After exclusion of subjects with diabetes in medical history (n=87) and/or
                        non-fasted glucose lower than 11 mmol/L (n=1) and/or use of glucose lowering
                        medication (n=37), a sample of 1625 subjects was available for the current
                        study. The Medical Ethical Committee of the Leiden University Medical Centre
                        approved the study and informed consent was obtained from all subjects.
                    
            </p><p>
                <underline>Biochemical analysis
                </underline>. All serum measurements were performed with fully automated equipment.
                        For insulin&#x02011;like growth factor-1 (IGF-1), insulin-like growth factor
                        binding protein 3 (IGFBP3) and insulin, the Immulite 2500 from DPC (Los Angeles, CA, USA) was applied. CVs for these measurements were all below 8%. For
                        glucose, total cholesterol, HDL-cholesterol, triglycerides, free fatty acids
                        (FFA) the Hitachi Modular or the Cobas Integra 800, both from Roche, Almere,
                        the Netherlands were applied. CVs of these measurements were all below 5 %.
                    
            </p><p>
                <underline>Medication use
                </underline><italic>.</italic> Lipid lowering agents were
                        defined as fibrates, niacin, bile acid sequestrants, 3-hydroxy-3-methylglutaryl-coenzyme
                        Areductase inhibitors (ATC code C10).
                    
            </p><p>
                <underline>Calculations and statistical analysis.
                </underline> For estimation of the level of LDL cholesterol the
                        Friedewald formula was applied (LDL cholesterol [mmol/l] = total cholesterol -
                        HDL cholesterol - [triglycerides/2.2]), whereby participants with a
                        triglyceride concentration higher than 443 mg/dl (5 mmol/l) were excluded. For
                        molar comparisons between IGF-1 and IGFBP3, the following molecular masses were
                        used in the calculation: IGF-1: 7.5 kDa and IGFBP3: 28.5 kDa.
                    
            </p><p>Distributions of continuous variables were examined
                        for normality and logarithmically transformed, when appropriate and used in all
                        calculations. Geometric means (with 95% confidence intervals (CI)) are reported
                        for transformed variables (insulin, triglycerides and free fatty acids). All
                        differences in mean serum levels and anthropometrics between the groups of
                        offspring and partners were assessed with the use of linear regression,
                        adjusted for sex, age and correlation of sibling data using robust standard
                        errors in STATA. The relation between IGF-1/IGFBP3 molar ratio (expressed in
                        Z-scores and restricted to values within 3 standard deviations (SDs) from the
                        mean) and glucose was assessed with the use of a linear mixed model, adjusted
                        for sex, age and correlation of sibling data in SPSS. The cumulative
                        distributions of IGF-1, IGFBP3 and height were calculated in SPSS. The change
                        in levels of IGF-1, IGFBP3 over chronological age as a continuous variable was
                        assessed with the use of a linear mixed model, adjusted for age and correlation
                        of sibling data in SPSS. The Statistical Package for the Social Sciences (SPSS)
                        program for Windows, version 14.0, and STATA version 10.0 were used for data
                        analysis, and plots were drawn in Excel.
                    
            </p></sec></body><back><ack><p>The LLS was funded by the Innovation Oriented research
                        Program on Genomics (SenterNovem; IGE01014 and IGE5007), the Centre for Medical
                        Systems Biology (CMSB), the Netherlands Genomics Initiative/Netherlands
                        Organization for scientific research (NGI/NWO; 05040202 and 050-060-810 (NCHA))
                        and the EU funded Network of Excellence Lifespan (FP6 036894). Rudi G.J.
                        Westendorp is supported by an unrestricted grant from the Netherlands Genomics
                        Initiative (NCHA 050-060-810). We thank all participants of the Leiden
                        Longevity Study for their consistent cooperation, as well all participating
                        general practitioners and pharmacists, the secretary staff (Meriam H van der
                        Star, Ellen H Bemer-Oorschot) and research nurses (Corrie J Groenendijk), data
                        managers (Karin H Herbschleb) for their expert contribution.
                    
            </p></ack><ref-list><title>References</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><name><surname>Oeppen</surname><given-names>J</given-names></name><name><surname>Vaupel</surname><given-names>JW</given-names></name><article-title>Demography. Broken limits to life expectancy</article-title><source>Science</source><year>2002</year><volume>296</volume><fpage>1029</fpage><lpage>1031</lpage><pub-id pub-id-type="pmid">12004104</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><name><surname>Schoenmaker</surname><given-names>M</given-names></name><name><surname>de Craen</surname><given-names>AJ</given-names></name><name><surname>de Meijer</surname><given-names>PH</given-names></name><name><surname>Beekman</surname><given-names>M</given-names></name><name><surname>Blauw</surname><given-names>GJ</given-names></name><name><surname>Slagboom</surname><given-names>PE</given-names></name><name><surname>Westendorp</surname><given-names>RG</given-names></name><article-title>Evidence of genetic enrichment for exceptional survival using a family approach: the Leiden Longevity Study</article-title><source>Eur J Hum Genet</source><year>2006</year><volume>14</volume><fpage>79</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">16251894</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><name><surname>Westendorp</surname><given-names>RGJ</given-names></name><name><surname>van</surname><given-names>Heemst D</given-names></name><name><surname>Rozing</surname><given-names>MP</given-names></name><name><surname>Frohlich</surname><given-names>M</given-names></name><name><surname>de Craen</surname><given-names>AJM</given-names></name><name><surname>Beekman</surname><given-names>M</given-names></name><name><surname>Heijmans</surname><given-names>BT</given-names></name><name><surname>Mooijaart</surname><given-names>SP</given-names></name><name><surname>Blauw</surname><given-names>GJ</given-names></name><name><surname>Slagboom</surname><given-names>PE</given-names></name><article-title>Nonagenarian siblings and their offspring display lower risk of mortality and morbidity than sporadic nonagenarians: The Leiden Longevity Study</article-title><source>J Am Geriatr Soc</source><year>2009</year><comment>In press
                    </comment></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><name><surname>Terry</surname><given-names>DF</given-names></name><name><surname>Wilcox</surname><given-names>M</given-names></name><name><surname>McCormick</surname><given-names>MA</given-names></name><name><surname>Lawler</surname><given-names>E</given-names></name><name><surname>Perls</surname><given-names>TT</given-names></name><article-title>Cardiovascular advantages among the offspring of centenarians</article-title><source>J Gerontol A Biol Sci Med Sci</source><year>2003</year><volume>58</volume><fpage>M425</fpage><lpage>M431</lpage><pub-id pub-id-type="pmid">12730251</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><name><surname>Atzmon</surname><given-names>G</given-names></name><name><surname>Schechter</surname><given-names>C</given-names></name><name><surname>Greiner</surname><given-names>W</given-names></name><name><surname>Davidson</surname><given-names>D</given-names></name><name><surname>Rennert</surname><given-names>G</given-names></name><name><surname>Barzilai</surname><given-names>N</given-names></name><article-title>Clinical phenotype of families with longevity</article-title><source>J Am Geriatr Soc</source><year>2004</year><volume>52</volume><fpage>274</fpage><lpage>277</lpage><pub-id pub-id-type="pmid">14728640</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><name><surname>Bartke</surname><given-names>A</given-names></name><article-title>Impact of reduced insulin-like growth factor-1/insulin signaling on aging in mammals: novel findings</article-title><source>Aging Cell</source><year>2008</year><volume>7</volume><fpage>285</fpage><lpage>290</lpage><pub-id pub-id-type="pmid">18346217</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><name><surname>Kenyon</surname><given-names>C</given-names></name><article-title>A conserved regulatory system for aging</article-title><source>Cell</source><year>2001</year><volume>105</volume><fpage>165</fpage><lpage>168</lpage><pub-id pub-id-type="pmid">11336665</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><name><surname>Tatar</surname><given-names>M</given-names></name><name><surname>Kopelman</surname><given-names>A</given-names></name><name><surname>Epstein</surname><given-names>D</given-names></name><name><surname>Tu</surname><given-names>MP</given-names></name><name><surname>Yin</surname><given-names>CM</given-names></name><name><surname>Garofalo</surname><given-names>RS</given-names></name><article-title>A mutant Drosophila insulin receptor homolog that extends life-span and impairs neuroendocrine function</article-title><source>Science</source><year>2001</year><volume>292</volume><fpage>107</fpage><lpage>110</lpage><pub-id pub-id-type="pmid">11292875</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><name><surname>Clancy</surname><given-names>DJ</given-names></name><name><surname>Gems</surname><given-names>D</given-names></name><name><surname>Harshman</surname><given-names>LG</given-names></name><name><surname>Oldham</surname><given-names>S</given-names></name><name><surname>Stocker</surname><given-names>H</given-names></name><name><surname>Hafen</surname><given-names>E</given-names></name><name><surname>Leevers</surname><given-names>SJ</given-names></name><name><surname>Partridge</surname><given-names>L</given-names></name><article-title>Extension of life-span by loss of CHICO, a Drosophila insulin receptor substrate protein</article-title><source>Science</source><year>2001</year><volume>292</volume><fpage>104</fpage><lpage>106</lpage><pub-id pub-id-type="pmid">11292874</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><name><surname>Bluher</surname><given-names>M</given-names></name><name><surname>Kahn</surname><given-names>BB</given-names></name><name><surname>Kahn</surname><given-names>CR</given-names></name><article-title>Extended longevity in mice lacking the insulin receptor in adipose tissue</article-title><source>Science</source><year>2003</year><volume>299</volume><fpage>572</fpage><lpage>574</lpage><pub-id pub-id-type="pmid">12543978</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><name><surname>Selman</surname><given-names>C</given-names></name><name><surname>Lingard</surname><given-names>S</given-names></name><name><surname>Choudhury</surname><given-names>AI</given-names></name><name><surname>Batterham</surname><given-names>RL</given-names></name><name><surname>Claret</surname><given-names>M</given-names></name><name><surname>Clements</surname><given-names>M</given-names></name><name><surname>Ramadani</surname><given-names>F</given-names></name><name><surname>Okkenhaug</surname><given-names>K</given-names></name><name><surname>Schuster</surname><given-names>E</given-names></name><name><surname>Blanc</surname><given-names>E</given-names></name><name><surname>Piper</surname><given-names>MD</given-names></name><name><surname>Al-Qassab</surname><given-names>H</given-names></name><name><surname>Speakman</surname><given-names>JR</given-names></name><article-title>Evidence for lifespan extension and delayed age-related biomarkers in insulin receptor substrate 1 null mice</article-title><source>FASEB J</source><year>2008</year><volume>22</volume><fpage>807</fpage><lpage>818</lpage><pub-id pub-id-type="pmid">17928362</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><name><surname>Taguchi</surname><given-names>A</given-names></name><name><surname>Wartschow</surname><given-names>LM</given-names></name><name><surname>White</surname><given-names>MF</given-names></name><article-title>Brain IRS2 signaling coordinates life span and nutrient homeostasis</article-title><source>Science</source><year>2007</year><volume>317</volume><fpage>369</fpage><lpage>372</lpage><pub-id pub-id-type="pmid">17641201</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><name><surname>Brown-Borg</surname><given-names>HM</given-names></name><name><surname>Borg</surname><given-names>KE</given-names></name><name><surname>Meliska</surname><given-names>CJ</given-names></name><name><surname>Bartke</surname><given-names>A</given-names></name><article-title>Dwarf mice and the ageing process</article-title><source>Nature</source><year>1996</year><volume>384</volume><fpage>33</fpage><pub-id pub-id-type="pmid">8900272</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><name><surname>Flurkey</surname><given-names>K</given-names></name><name><surname>Papaconstantinou</surname><given-names>J</given-names></name><name><surname>Miller</surname><given-names>RA</given-names></name><name><surname>Harrison</surname><given-names>DE</given-names></name><article-title>Lifespan extension and delayed immune and collagen aging in mutant mice with defects in growth hormone production</article-title><source>Proc Natl Acad Sci U S A</source><year>2001</year><volume>98</volume><fpage>6736</fpage><lpage>6741</lpage><pub-id pub-id-type="pmid">11371619</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><name><surname>Chandrashekar</surname><given-names>V</given-names></name><name><surname>Bartke</surname><given-names>A</given-names></name><name><surname>Coschigano</surname><given-names>KT</given-names></name><name><surname>Kopchick</surname><given-names>JJ</given-names></name><article-title>Pituitary and testicular function in growth hormone receptor gene knockout mice</article-title><source>Endocrinology</source><year>1999</year><volume>140</volume><fpage>1082</fpage><lpage>1088</lpage><pub-id pub-id-type="pmid">10067829</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><name><surname>Holzenberger</surname><given-names>M</given-names></name><name><surname>Dupont</surname><given-names>J</given-names></name><name><surname>Ducos</surname><given-names>B</given-names></name><name><surname>Leneuve</surname><given-names>P</given-names></name><name><surname>Geloen</surname><given-names>A</given-names></name><name><surname>Even</surname><given-names>PC</given-names></name><name><surname>Cervera</surname><given-names>P</given-names></name><name><surname>Le</surname><given-names>BY</given-names></name><article-title>IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice</article-title><source>Nature</source><year>2003</year><volume>421</volume><fpage>182</fpage><lpage>187</lpage><pub-id pub-id-type="pmid">12483226</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><name><surname>Juul</surname><given-names>A</given-names></name><article-title>Serum levels of insulin-like growth factor I and its binding proteins in health and disease</article-title><source>Growth Horm IGF Res</source><year>2003</year><volume>13</volume><fpage>113</fpage><lpage>170</lpage><pub-id pub-id-type="pmid">12914749</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><name><surname>Iranmanesh</surname><given-names>A</given-names></name><name><surname>Lizarralde</surname><given-names>G</given-names></name><name><surname>Veldhuis</surname><given-names>JD</given-names></name><article-title>Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men</article-title><source>J Clin Endocrinol Metab</source><year>1991</year><volume>73</volume><fpage>1081</fpage><lpage>1088</lpage><pub-id pub-id-type="pmid">1939523</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><name><surname>Lamberts</surname><given-names>SW</given-names></name><name><surname>van den Beld</surname><given-names>AW</given-names></name><name><surname>van der Lely</surname><given-names>AJ</given-names></name><article-title>The endocrinology of aging</article-title><source>Science</source><year>1997</year><volume>278</volume><fpage>419</fpage><lpage>424</lpage><pub-id pub-id-type="pmid">9334293</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><name><surname>Arai</surname><given-names>Y</given-names></name><name><surname>Hirose</surname><given-names>N</given-names></name><name><surname>Yamamura</surname><given-names>K</given-names></name><name><surname>Shimizu</surname><given-names>K</given-names></name><name><surname>Takayama</surname><given-names>M</given-names></name><name><surname>Ebihara</surname><given-names>Y</given-names></name><name><surname>Osono</surname><given-names>Y</given-names></name><article-title>Serum insulin-like growth factor-1 in centenarians: implications of IGF-1 as a rapid turnover protein</article-title><source>J Gerontol A Biol Sci Med Sci</source><year>2001</year><volume>56</volume><fpage>M79</fpage><lpage>M82</lpage><pub-id pub-id-type="pmid">11213280</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><name><surname>Cappola</surname><given-names>AR</given-names></name><name><surname>Xue</surname><given-names>QL</given-names></name><name><surname>Ferrucci</surname><given-names>L</given-names></name><name><surname>Guralnik</surname><given-names>JM</given-names></name><name><surname>Volpato</surname><given-names>S</given-names></name><name><surname>Fried</surname><given-names>LP</given-names></name><article-title>Insulin-like growth factor I and interleukin-6 contribute synergistically to disability and mortality in older women</article-title><source>J Clin Endocrinol Metab</source><year>2003</year><volume>88</volume><fpage>2019</fpage><lpage>2025</lpage><pub-id pub-id-type="pmid">12727948</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><name><surname>Kuningas</surname><given-names>M</given-names></name><name><surname>Mooijaart</surname><given-names>SP</given-names></name><name><surname>van</surname><given-names>HD</given-names></name><name><surname>Zwaan</surname><given-names>BJ</given-names></name><name><surname>Slagboom</surname><given-names>PE</given-names></name><name><surname>Westendorp</surname><given-names>RG</given-names></name><article-title>Genes encoding longevity: from model organisms to humans</article-title><source>Aging Cell</source><year>2008</year><volume>7</volume><fpage>270</fpage><lpage>280</lpage><pub-id pub-id-type="pmid">18208581</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><name><surname>van</surname><given-names>Heemst D</given-names></name><name><surname>Beekman</surname><given-names>M</given-names></name><name><surname>Mooijaart</surname><given-names>SP</given-names></name><name><surname>Heijmans</surname><given-names>BT</given-names></name><name><surname>Brandt</surname><given-names>BW</given-names></name><name><surname>Zwaan</surname><given-names>BJ</given-names></name><name><surname>Slagboom</surname><given-names>PE</given-names></name><name><surname>Westendorp</surname><given-names>RG</given-names></name><article-title>Reduced insulin/IGF-1 signalling and human longevity</article-title><source>Aging Cell</source><year>2005</year><volume>4</volume><fpage>79</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">15771611</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><name><surname>Suh</surname><given-names>Y</given-names></name><name><surname>Atzmon</surname><given-names>G</given-names></name><name><surname>Cho</surname><given-names>MO</given-names></name><name><surname>Hwang</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Leahy</surname><given-names>DJ</given-names></name><name><surname>Barzilai</surname><given-names>N</given-names></name><name><surname>Cohen</surname><given-names>P</given-names></name><article-title>Functionally significant insulin-like growth factor I receptor mutations in centenarians</article-title><source>Proc Natl Acad Sci U S A</source><year>2008</year><volume>105</volume><fpage>3438</fpage><lpage>3442</lpage><pub-id pub-id-type="pmid">18316725</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><name><surname>Ferrannini</surname><given-names>E</given-names></name><name><surname>Vichi</surname><given-names>S</given-names></name><name><surname>Beck-Nielsen</surname><given-names>H</given-names></name><name><surname>Laakso</surname><given-names>M</given-names></name><name><surname>Paolisso</surname><given-names>G</given-names></name><name><surname>Smith</surname><given-names>U</given-names></name><article-title>Insulin action and age. European Group for the Study of Insulin Resistance (EGIR)</article-title><source>Diabetes</source><year>1996</year><volume>45</volume><fpage>947</fpage><lpage>953</lpage><pub-id pub-id-type="pmid">8666147</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><name><surname>Paolisso</surname><given-names>G</given-names></name><name><surname>Gambardella</surname><given-names>A</given-names></name><name><surname>Ammendola</surname><given-names>S</given-names></name><name><surname>D'Amore</surname><given-names>A</given-names></name><name><surname>Balbi</surname><given-names>V</given-names></name><name><surname>Varricchio</surname><given-names>M</given-names></name><name><surname>D'Onofrio</surname><given-names>F</given-names></name><article-title>Glucose tolerance and insulin action in healty centenarians</article-title><source>Am J Physiol</source><year>1996</year><volume>270</volume><fpage>E890</fpage><lpage>E894</lpage><pub-id pub-id-type="pmid">8967479</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><name><surname>Paolisso</surname><given-names>G</given-names></name><name><surname>Ammendola</surname><given-names>S</given-names></name><name><surname>Del</surname><given-names>BA</given-names></name><name><surname>Gambardella</surname><given-names>A</given-names></name><name><surname>Riondino</surname><given-names>M</given-names></name><name><surname>Tagliamonte</surname><given-names>MR</given-names></name><name><surname>Rizzo</surname><given-names>MR</given-names></name><name><surname>Carella</surname><given-names>C</given-names></name><name><surname>Varricchio</surname><given-names>M</given-names></name><article-title>Serum levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 in healthy centenarians: relationship with plasma leptin and lipid concentrations, insulin action, and cognitive function</article-title><source>J Clin Endocrinol Metab</source><year>1997</year><volume>82</volume><fpage>2204</fpage><lpage>2209</lpage><pub-id pub-id-type="pmid">9215295</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><name><surname>Muzumdar</surname><given-names>RH</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Fishman</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Atzmon</surname><given-names>G</given-names></name><name><surname>Vuguin</surname><given-names>P</given-names></name><name><surname>Einstein</surname><given-names>FH</given-names></name><name><surname>Hwang</surname><given-names>D</given-names></name><name><surname>Cohen</surname><given-names>P</given-names></name><name><surname>Barzilai</surname><given-names>N</given-names></name><article-title>Central and opposing effects of IGF-I and IGF-binding protein-3 on systemic insulin action</article-title><source>Diabetes</source><year>2006</year><volume>55</volume><fpage>2788</fpage><lpage>2796</lpage><pub-id pub-id-type="pmid">17003344</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><name><surname>Sherwin</surname><given-names>RS</given-names></name><name><surname>Borg</surname><given-names>WP</given-names></name><name><surname>Boulware</surname><given-names>SD</given-names></name><article-title>Metabolic effects of insulin-like growth factor I in normal humans</article-title><source>Horm Res</source><year>1994</year><volume>41 Suppl 2</volume><fpage>97</fpage><lpage>101</lpage><pub-id pub-id-type="pmid">8088711</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><name><surname>Sandhu</surname><given-names>MS</given-names></name><name><surname>Heald</surname><given-names>AH</given-names></name><name><surname>Gibson</surname><given-names>JM</given-names></name><name><surname>Cruickshank</surname><given-names>JK</given-names></name><name><surname>Dunger</surname><given-names>DB</given-names></name><name><surname>Wareham</surname><given-names>NJ</given-names></name><article-title>Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study</article-title><source>Lancet</source><year>2002</year><volume>359</volume><fpage>1740</fpage><lpage>1745</lpage><pub-id pub-id-type="pmid">12049864</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><name><surname>Redman</surname><given-names>LM</given-names></name><name><surname>Martin</surname><given-names>CK</given-names></name><name><surname>Williamson</surname><given-names>DA</given-names></name><name><surname>Ravussin</surname><given-names>E</given-names></name><article-title>Effect of caloric restriction in non-obese humans on physiological, psychological and behavioral outcomes</article-title><source>Physiol Behav</source><year>2008</year><volume>94</volume><fpage>643</fpage><lpage>648</lpage><pub-id pub-id-type="pmid">18502453</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><name><surname>Bonafe</surname><given-names>M</given-names></name><name><surname>Barbieri</surname><given-names>M</given-names></name><name><surname>Marchegiani</surname><given-names>F</given-names></name><name><surname>Olivieri</surname><given-names>F</given-names></name><name><surname>Ragno</surname><given-names>E</given-names></name><name><surname>Giampieri</surname><given-names>C</given-names></name><name><surname>Mugianesi</surname><given-names>E</given-names></name><name><surname>Centurelli</surname><given-names>M</given-names></name><name><surname>Franceschi</surname><given-names>C</given-names></name><name><surname>Paolisso</surname><given-names>G</given-names></name><article-title>Polymorphic variants of insulin-like growth factor I (IGF-I) receptor and phosphoinositide 3-kinase genes affect IGF-I plasma levels and human longevity: cues for an evolutionarily conserved mechanism of life span control</article-title><source>J Clin Endocrinol Metab</source><year>2003</year><volume>88</volume><fpage>3299</fpage><lpage>3304</lpage><pub-id pub-id-type="pmid">12843179</pub-id></element-citation></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors of this manuscript have no conflict of
                            interests to declare.
                        
                </p></fn></fn-group></back></article>